

Version 4.1      Revision Date: 31.01.2019      SDS Number: 20511      Date of last issue: 16.10.2018  
Date of first issue: 18.09.2017

---

## SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

### 1.1 Product identifier

## NEXIUM IV POWDER FOR SOLUTION FOR INJECTION/INFUSION

Details of the supplier of the safety data sheet : ASTRAZENECA PTY LTD      Emergency Telephone  
PO Box 131      +44 (0) 1235 239 670  
66 Talavera Rd, North Ryde  
NSW 2113  
AUSTRALIA  
+61 2 9978 3500

SafetyDataSheets.AlderleyPark@astrazeneca.com

### Alternative Names

Esomeprazole i.v.  
CAS No. : Not applicable

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Symptomatic treatment of gastro-oesophageal reflux disease (GERD)

---

## SECTION 2. HAZARDS IDENTIFICATION

### GHS Classification

Acute toxicity (Oral) : Category 4  
Serious eye damage/eye irritation : Category 2A  
Skin sensitisation : Category 1  
Short-term (acute) aquatic hazard : Category 3  
Long-term (chronic) aquatic hazard : Category 2

### GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H302 Harmful if swallowed.  
H317 May cause an allergic skin reaction.  
H319 Causes serious eye irritation.  
H402 Harmful to aquatic life.  
H411 Toxic to aquatic life with long lasting effects.

Version 4.1      Revision Date: 31.01.2019      SDS Number: 20511      Date of last issue: 16.10.2018  
 Date of first issue: 18.09.2017

Precautionary statements : **Prevention:**  
 P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.  
 P264 Wash skin thoroughly after handling.  
 P272 Contaminated work clothing should not be allowed out of the workplace.  
 P273 Avoid release to the environment.  
 P280 Wear protective gloves/ eye protection/ face protection.

**Response:**  
 P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell. Rinse mouth.  
 P302 + P352 IF ON SKIN: Wash with plenty of soap and water.  
 P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
 P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.  
 P337 + P313 If eye irritation persists: Get medical advice/ attention.  
 P391 Collect spillage.

**Disposal:**  
 P501 Dispose of contents/ container to an approved waste disposal plant.

#### Other hazards which do not result in classification

Dust may be irritant to the respiratory tract.  
 May cause skin irritation.  
 May form explosible dust-air mixture if dispersed.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Esomeprazole sodium	161796-78-7	89 -97
Disodium edetate B.P.	6381-92-6	3.3 -6.5

### SECTION 4. FIRST AID MEASURES

If inhaled : Remove patient from exposure, keep warm and at rest.  
 Obtain medical attention if ill effects occur.

In case of skin contact : Take off all contaminated clothing immediately.  
 After contact with skin, wash immediately with plenty of soap and water.  
 Obtain medical attention.

In case of eye contact : Immediately irrigate with eyewash solution or clean water,  
 holding the eyelids apart, for at least 10 minutes.  
 Obtain immediate medical attention.

# SAFETY DATA SHEET



Version 4.1      Revision Date: 31.01.2019      SDS Number: 20511      Date of last issue: 16.10.2018  
Date of first issue: 18.09.2017

---

- If swallowed : Wash out mouth with water and give 200-300ml of water to drink.  
Do NOT induce vomiting as a First-Aid measure.  
Obtain medical attention if ill effects occur.
- Most important symptoms and effects, both acute and delayed : Refer to sections 2 and 11  
Harmful if swallowed.  
May cause an allergic skin reaction.  
Causes serious eye irritation.
- Notes to physician : Symptomatic treatment and supportive therapy as indicated.  
For further detail consult the prescribing information.
- 

## SECTION 5. FIREFIGHTING MEASURES

- Suitable extinguishing media : water spray, foam, dry powder or CO<sub>2</sub>.
- Unsuitable extinguishing media : Avoid high pressure media which could cause the formation of a potentially explosible dust-air mixture.
- Specific hazards during firefighting : If involved in a fire, it may burn and emit noxious and toxic fumes.
- Special protective equipment for firefighters : A self contained breathing apparatus and suitable protective clothing should be worn in fire conditions.  
Prevent fire extinguishing water from contaminating surface water or the ground water system.
- 

## SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Ensure suitable personal protection during removal of spillages.  
Avoid dispersal of dust in the air.  
See Section 8.
- Environmental precautions : Prevent entry into drains, sewers or watercourses.  
Collect spillage.
- Methods and materials for containment and cleaning up : Moisten spillages with water.  
Transfer to a container for disposal.  
Wash the spillage area with water.  
Avoid release to the environment.
- See section 13.
- 

## SECTION 7. HANDLING AND STORAGE

- Advice on safe handling : Do not breathe dust.  
Avoid contact with skin and eyes.  
Minimize dust generation and accumulation.  
The material may form explosible dust-air mixture if dispersed.  
Dust clouds may be extremely sensitive to ignition by electrostatic discharge and other ignition sources. Ensure good earthing of equipment and personnel.
-

Version 4.1      Revision Date: 31.01.2019      SDS Number: 20511      Date of last issue: 16.10.2018  
 Date of first issue: 18.09.2017

Conditions for safe storage : Store in original containers.  
 Protect from light.  
 Store at room temperature.

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Esomeprazole sodium	161796-78-7	TWA	0.1 mg/m <sup>3</sup>	COM; HYG

**Engineering measures** : The specific controls will depend on local circumstances and should be based on the risk assessment. Appropriate controls to reduce exposure may include engineering controls, for example ventilation, procedural controls and the use of personal protection equipment.

Prevent entry into drains, sewers or watercourses.  
 See Section 6 for environmental precautions.

### Personal protective equipment

- Respiratory protection** : Use a negative pressure air purifying respirator (full face mask) with filter class P3 if the risk assessment does not support the selection of other protection.
- Eye protection** : Use goggles to protect against direct contact with the product if the risk assessment does not support the selection of other protection.
- Skin and body protection** : Use impervious clothing to protect against direct contact with the product if the risk assessment does not support the selection of other protection. Use impervious protective gloves to protect against direct contact with the product. If the product is dissolved or wetted use a glove material that is resistant to the solvent/liquid.
- Protective measures** : Decisions about whether the use of personal protective equipment (PPE) is appropriate as part of the control strategy should be based on the workplace risk assessment and should take account of local legislative requirements for selection and use. There are multiple factors that will affect the specific requirements such as amount and concentration of the material, duration of exposure, frequency of exposure, external environmental conditions, the task, the user etc. All the information above should not be used in isolation and should be considered in the context of the workplace risk assessment on a case by case basis.

The recommended personal protective equipment (PPE) is

# SAFETY DATA SHEET



Version 4.1      Revision Date: 31.01.2019      SDS Number: 20511      Date of last issue: 16.10.2018  
Date of first issue: 18.09.2017

---

based on preventing the potential adverse health effects from exposure to the active pharmaceutical ingredient (API). The risk of exposure to the API in the formulation/product needs to be taken into consideration.

---

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Powder for solution.

Colour : white to off-white

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/range : No data available

Initial boiling point and boiling range : Not applicable

Flash point : No data available

Evaporation rate : Not applicable

Flammability (solid, gas) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Solubility(ies)  
Water solubility : No data available

Solubility in other solvents : No data available

Partition coefficient: n-octanol/water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, dynamic : Not applicable

# SAFETY DATA SHEET



Version 4.1      Revision Date: 31.01.2019      SDS Number: 20511      Date of last issue: 16.10.2018  
Date of first issue: 18.09.2017

---

Viscosity, kinematic                   : Not applicable  
Explosive properties                    : No data available  
Oxidizing properties                    : Not applicable

---

## SECTION 10. STABILITY AND REACTIVITY

Reactivity                                : No known reactivity hazard under normal conditions.  
Chemical stability                       : Stable under normal conditions.  
Possibility of hazardous reactions   : None known.  
Conditions to avoid                     : No conditions producing hazardous situations known.  
Incompatible materials                 : Acids  
  (decomposes)  
Hazardous decomposition products   : No hazardous decomposition products are known.

---

## SECTION 11. TOXICOLOGICAL INFORMATION

### 11.1 Acute toxicity

Harmful if swallowed.

#### **Product:**

Acute oral toxicity                     : Acute toxicity estimate: 483.09 mg/kg  
Method: Calculation method

#### **Components:**

##### **Esomeprazole sodium:**

Acute oral toxicity                     : Evident toxicity with mortality in rats at a dose of: 480 mg/kg  
Assessment: The component/mixture is moderately toxic after  
single ingestion.

Remarks: Information refers to  
Esomeprazole

Acute inhalation toxicity             : Remarks: May cause effects as described under single  
exposure.(STOT)

Acute dermal toxicity                  : Remarks: No information available.

##### **Disodium edetate B.P.:**

Acute oral toxicity                     : Assessment: The component/mixture is moderately toxic after  
single ingestion.

Version 4.1      Revision Date: 31.01.2019      SDS Number: 20511      Date of last issue: 16.10.2018  
Date of first issue: 18.09.2017

---

## 11.2 Skin corrosion/irritation

Not classified based on available information.

### Components:

#### **Esomeprazole sodium:**

Result : Mild skin irritation

#### **Disodium edetate B.P.:**

Result : Irritating to skin.

## 11.3 Serious eye damage/eye irritation

Causes serious eye irritation.

### Components:

#### **Esomeprazole sodium:**

Result : irritating

Remarks : May cause conjunctivitis.

#### **Disodium edetate B.P.:**

Result : Irritating to eyes.

## 11.4 Respiratory or skin sensitisation

### **Skin sensitisation**

May cause an allergic skin reaction.

### **Respiratory sensitisation**

Not classified based on available information.

### Components:

#### **Esomeprazole sodium:**

Result : May cause sensitisation by skin contact.

Remarks : Omeprazole:

It is an extreme skin sensitiser in animal tests.

Many cases of occupational skin sensitisation have been reported.

### **Chronic toxicity**

## 11.5 Germ cell mutagenicity

Not classified based on available information.

### Components:

#### **Esomeprazole sodium:**

Germ cell mutagenicity - Assessment : The substance is not considered to be genotoxic.

## 11.6 Carcinogenicity

Not classified based on available information.

Version 4.1      Revision Date: 31.01.2019      SDS Number: 20511      Date of last issue: 16.10.2018  
Date of first issue: 18.09.2017

---

**Components:****Esomeprazole sodium:**

Carcinogenicity - Assessment : The substance is not considered to be carcinogenic.

**11.7 Reproductive toxicity**

Not classified based on available information.

**Components:****Esomeprazole sodium:**

Reproductive toxicity - Assessment : There is no evidence of reprotoxicity in animal tests.

**11.8 STOT - single exposure**

Not classified based on available information.

**Components:****Esomeprazole sodium:**

Exposure routes : Oral, Inhalation  
Remarks : May cause nausea and vomiting.  
Rare cases of hypersensitivity (including allergic reactions) and CNS-effects (including dizziness and muscle jerks) have been reported in patients.

Exposure routes : Inhalation  
Remarks : Dust may be irritant to the respiratory tract.

**Disodium edetate B.P.:**

Assessment : May cause respiratory irritation.

**11.9 STOT - repeated exposure**

Not classified based on available information.

**Components:****Esomeprazole sodium:**

Exposure routes : Oral  
Target Organs : Stomach  
Remarks : Repeated exposure may produce adverse effects.  
These effects are derived from studies in animals.

Remarks : Common side effects reported from patients include headache, gastrointestinal disorders, sinusitis and respiratory infection.  
May cause effects as described under single exposure.(STOT)

**11.10 Aspiration toxicity**

Not classified based on available information.



Version 4.1      Revision Date: 31.01.2019      SDS Number: 20511      Date of last issue: 16.10.2018  
Date of first issue: 18.09.2017

---

**Components:****Esomeprazole sodium:**

No information available.

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Esomeprazole sodium:**

- Toxicity to fish : LC50 (Danio rerio (zebra fish)): 42 mg/l  
Exposure time: 96 H  
Method: OECD Test Guideline 203  
Remarks: (Omeprazole sodium)
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 H  
Method: OECD Test Guideline 202  
Remarks: (Omeprazole sodium)
- Toxicity to algae : EbC50 (green algae): 19 mg/l  
Exposure time: 72 H  
Method: OECD Test Guideline 201  
  
NOEC (green algae): 8.4 mg/l  
Exposure time: 72 H  
Test Type: growth rate  
Method: OECD Test Guideline 201
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1 mg/l  
Exposure time: 32 d  
Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 10 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211
- Toxicity to microorganisms : NOEC (activated sludge): 100 mg/l  
Exposure time: 3 H  
Method: OECD Test Guideline 209  
Remarks: There is no evidence of inhibition to the aerobic treatment process at a concentration of 100 mg/l.

**Persistence and degradability****Components:****Esomeprazole sodium:**

- Biodegradability : Result: not rapidly degradable  
Biodegradation: < 0.6 %  
Method: OECD Test Guideline 301C

# SAFETY DATA SHEET



Version 4.1      Revision Date: 31.01.2019      SDS Number: 20511      Date of last issue: 16.10.2018  
Date of first issue: 18.09.2017

---

## Bioaccumulative potential

### Components:

#### **Esomeprazole sodium:**

Bioaccumulation : Remarks: The substance has low potential for bioaccumulation.

## Mobility in soil

### Components:

#### **Esomeprazole sodium:**

Mobility : Remarks: Water solubility  $\geq 1$  mg/l.

Distribution among environmental compartments : Remarks: No information available.

## Other adverse effects

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### **Disposal methods**

Waste from residues : Disposal should be in accordance with local, state or national legislation.  
Waste, even small quantities, should never be poured down drains, sewers or water courses.  
Dispose of contents/ container to an approved incineration plant.

Contaminated packaging : Empty container will retain product residue. Observe all hazard precautions.

---

## SECTION 14. TRANSPORT INFORMATION

### ICAO/IATA

UN No. : 3077  
Proper Shipping Name : Environmentally hazardous substance, solid, n.o.s.  
(ESOMEPRAZOLE SODIUM)  
Class : 9  
Packing Group : III  
Environmental hazards : Environmentally hazardous

### IMO/IMDG

# SAFETY DATA SHEET



Version 4.1      Revision Date: 31.01.2019      SDS Number: 20511      Date of last issue: 16.10.2018  
Date of first issue: 18.09.2017

---

UN No. : 3077  
Proper Shipping Name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (ESOMEPRAZOLE SODIUM)  
Class : 9  
Packing Group : III  
Marine pollutant : Marine pollutant

## ADR

UN No. : 3077  
Proper Shipping Name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (ESOMEPRAZOLE SODIUM)  
Class : 9  
Label(s) : 9  
Packing Group : III  
Environmental hazards : Environmentally hazardous

---

## SECTION 15. REGULATORY INFORMATION

### Safety, health and environmental regulations/legislation specific for the substance or mixture

In order to comply with legal duties it is necessary to consult local and national legislation.

Standard for the Uniform Scheduling of Medicines and Poisons : No poison schedule number allocated

Prohibition/Licensing Requirements : There is no applicable prohibition or notification/licensing requirements, including for carcinogens under Commonwealth, State or Territory legislation.

### The components of this product are reported in the following inventories:

REACH : Not in compliance with the inventory

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.

Esomeprazole sodium  
Disodium edetate B.P.

AICS : Not in compliance with the inventory

ENCS : Not in compliance with the inventory

ISHL : Not in compliance with the inventory

# SAFETY DATA SHEET



Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2018
4.1	31.01.2019	20511	Date of first issue: 18.09.2017

IECSC : Not in compliance with the inventory

TCSI : Not in compliance with the inventory

TSCA : Not On TSCA Inventory

## SECTION 16. OTHER INFORMATION

### Further information

Revision Date : 31.01.2019

Other information : Minor changes:  
Administrative release.

Date format : dd.mm.yyyy

### Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; COM - In-house occupational exposure limit; CPR - Controlled Products Regulations; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HYG - Analytical method for occupational exposure monitoring; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; Sen - Capable of causing respiratory sensitization; Sk - Can be absorbed through skin, thus contributing to systemic effects; STEL - Short-term exposure limit 15-minutes time-weighted average; TLV - Threshold Limit Value (ACGIH); TLV-C - Threshold Limit Value Ceiling limit (ACGIH); TSCA - Toxic Substances Control Act (United States); TWA - Long-term exposure limit 8h time-weighted average; UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the

# SAFETY DATA SHEET

AstraZeneca 

 MedImmune

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2018
4.1	31.01.2019	20511	Date of first issue: 18.09.2017

---

specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

AU / EN